Monoamine oxidase inhibitors were among the first antidepressants to be discovered and
have long been used as such. It now seems that many of these agents might have …

Inhibitors of monoamine oxidase (MAO) were initially used in medicine following the
discovery of their antidepressant action. Subsequently their ability to potentiate the effects of …

Monoamine oxidase (MAO) is believed to mediate the degradation of monoamine
neurotransmitters, including dopamine, in the brain. Between the two types of MAO, MAO-B …

In animals, sporadic injections of the mitochondrial toxin 1-methyl-4-phenyl-1, 2, 3, 6-
tetrahydropyridine (MPTP) selectively damage dopaminergic neurons but do not fully …

Dopamine has effects on the mammalian heart. These effects can include an increase in the
force of contraction, and an elevation of the beating rate and the constriction of coronary …

The circadian clock has been implicated in addiction and several forms of depression [1, 2],
indicating interactions between the circadian and the reward systems in the brain [3–5] …

Abstract See Jellinger (doi: 10.1093/awx190) for a scientific commentary on this article. The
enzyme monoamine oxidases (B and A subtypes, encoded by MAOB and MAOA …

Current pharmacological treatments for Parkinson's disease (PD) are focused on
symptomatic relief, but not on disease modification, based on the strong belief that PD is …

HIGHLIGHTS ASS234 is a MTDL compound containing a moiety from Donepezil and the
propargyl group from the PF 9601N, a potent and selective MAO B inhibitor. This compound …

The mammalian target of rapamycin (mTOR) is an ubiquitously expressed serine-threonine
kinase, which senses and integrates several intracellular and environmental cues to …